- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05469373
ESIS em DRE Pediátrico
Estimulação elétrica para indução de convulsões em epilepsia refratária a medicamentos pediátricos (ESIS em toque retal pediátrico).
The main reason for this research study is to gain information about how the brain makes seizures by causing seizures using very small amounts of current, or electrical stimulation. Using small amounts of current to cause seizures (or stimulate) is not new at CCHMC - it is part of routine clinical practice for some patients at some electrodes.
This study differs from routine clinical care in that all study patients will undergo electrical stimulation in all or nearly all electrode contacts. The study team is doing this because there is promising data in adult patients that stimulating comprehensively (targeting all or nearly all of the electrode contacts) helps define the seizure network. Defining the seizure network in turn helps the medical team plan surgery. So far, there is not as much published data on seizure stimulation for pediatric patients.
This research study thus has the potential both to help individual patients (by providing specific information about your seizure networks) and to help pediatric patients with epilepsy in general (by increasing our understanding of stimulated seizures in children, teenagers and young adults).
Visão geral do estudo
Status
Condições
Descrição detalhada
Epilepsy affects about 1% of the population, with roughly 30% of patients with epilepsy eventually developing drug-resistant epilepsy (DRE). Increasingly, surgery is pursued for DRE, yielding seizure freedom rates of 50-70%. However, accurate deduction of the epileptogenic zone (EZ) for surgical planning can be difficult in pediatric DRE, especially in those cases of multifocal seizures, as is often seen in Tuberous Sclerosis Complex (TSC), for example. Patients with multifocal epilepsy typically require a period of pre-surgical invasive EEG monitoring to record spontaneous seizures, the gold standard for EZ deduction. Unfortunately, the invasive monitoring process may be lengthy, costly and even fail to reveal a dominant EZ.
Electrical stimulation of induced seizures (ESIS) using stereo EEG (sEEG) has been shown to be a safe and valid adjunct for EZ delineation in adults with DRE. ESIS can be implemented within 1-2 days of electrode implantation, while the patient would otherwise be passively awaiting spontaneous seizures. ESIS typically induces habitual seizures with few side effects, and there is no data to suggest that ESIS inhibits spontaneous seizures or prolongs the otherwise clinically-indicated hospital stay. Crucially, published data show that induced seizures provide information about the EZ that is both convergent with and unique from that provided by spontaneous seizures. Despite these promising reports, ESIS is not widely integrated into pediatric DRE evaluation.
The overall objective is to improve methods of EZ identification in pediatric DRE patients with complex EZs, thereby increasing the likelihood of surgical candidacy for patients and ultimately improving surgical outcomes. In this protocol, investigators hypothesize that electrical stimulation of induced seizures (ESIS) is an effective adjunct for EZ delineation in children with DRE. To test this, the study will enroll n=86 patients with DRE undergoing sEEG evaluation aged 1-30 years. Based on the CCHMC epilepsy surgery program throughput, it is anticipated that this will include approximately n=36 patients with TSC and n=50 without TSC, which will provide the opportunity to compare the utility of this technique between patients with and without TSC. Patients will undergo ESIS using published Cincinnati Children's Hospital Medical Center (CCHMC) parameters with modifications. Gray and white matter contacts will be stimulated systematically. Safety, tolerability, yield, validity and parameter space will be examined.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Participants with drug-refractory epilepsy who receive care at or are referred into the CCHMC Comprehensive Epilepsy Center will comprise the targeted study population. Specifically, those patients who undergo phase I evaluations and are subsequently recommended for phase II evaluations at CCHMC will be identified as research study candidates.
Descrição
Inclusion Criteria:
- Diagnosis of drug-refractory epilepsy (DRE)
- 1-30 years of age
- recommended to undergo stereoencephalography (sEEG) at CCHMC
Exclusion Criteria:
- <1 and >30 years of age
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: CASE_ONLY
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety -- Occurrence of generalized, convulsive and prolonged seizures
Prazo: Phase II epilepsy surgery testing
|
Evaluate the safety of ESIS in pediatric DRE patients. |
Phase II epilepsy surgery testing
|
|
Tolerability -- Quantify study withdrawal and patient/caregiver experience
Prazo: during Phase II epilepsy surgery testing
|
Evaluate the tolerability of ESIS in pediatric DRE patients. |
during Phase II epilepsy surgery testing
|
|
Yield -- Rate of induction of habitual seizures
Prazo: during Phase II epilepsy surgery testing
|
Evaluate the yield of ESIS in pediatric DRE patients. |
during Phase II epilepsy surgery testing
|
|
Clinical Validity
Prazo: during Phase II epilepsy surgery testing and through study completion, an average of 1 year
|
Test the clinical validity of ESIS in pediatric DRE patients by examining the impact of occurance of induced seizures on surgical outcomes. |
during Phase II epilepsy surgery testing and through study completion, an average of 1 year
|
|
Predictors
Prazo: during Phase II epilepsy surgery testing
|
Investigate the methodologic, anatomic, and patient-specific predictors of induced seizures in pediatric DRE patients. |
during Phase II epilepsy surgery testing
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Sarah Katie Ihnen, MD, PhD, Children's Hospital Medical Center, Cincinnati
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Neoplasias
- Doenças Genéticas, Congênitas
- Doenças Neurodegenerativas
- Anomalias congénitas
- Distúrbios Heredodegenerativos, Sistema Nervoso
- Síndromes Neoplásicas Hereditárias
- Síndromes Neurocutâneas
- Hamartoma
- Neoplasias Múltiplas Primárias
- Malformações do Desenvolvimento Cortical, Grupo I
- Malformações do Desenvolvimento Cortical
- Malformações do Sistema Nervoso
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Epilepsia resistente a medicamentos
- Esclerose Tuberosa
- Epilepsia
Outros números de identificação do estudo
- 2022-0020
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .